Session Type: Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are part of the spondylarthritis spectrum that can be treated with secukinumab, a fully human IgG1 monoclonal antibody targeting interleukin-17A. Real-word data on long-term secukinumab effectiveness in these two diseases are limited. In separate cohorts of axSpA and PsA patients treated with secukinumab in routine care, we aimed to assess a) 24-, and 48-month retention rates; and b) proportions of patients achieving 24-, and 48-month composite scores of remission and response.
Methods: Patients with axSpA and PsA who initiated secukinumab were included from 13 registriesparticipating in the European Spondyloarthritis (EuroSpA) Research Collaboration Network . Kaplan-Meier plots with log-rank tests and Cox regression analyses were performed to assess 24-, and 48-month secukinumab retention rates overall, and compared by prior b/tsDMARD status (0/1/≥2). Comparisons of remission and response rates according to b/tsDMARDs status, were performed by logistic regression adjusted for age, gender, register, time since diagnosis and disease activity at treatment start (baseline). Missing baseline data were imputed by multivariate imputation by chained equations.
Results: A total of 767 axSpA and 975 PsA patients from 13 and 12 countries, respectively, were included. At baseline, axSpA patients had a median (IQR) age of 47 (38-55) years, were predominantly male (60%), and had high disease activity (median (IQR)Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP 3.6 (2.9-4.2)). PsA patients had a median (IQR) age of 52 (44-59) years, were predominantly female (56%), and had moderate disease activity (median (IQR) Disease Activity index for PSoriatic Arthritis in 28 joints (DAPSA28) 25.1 (16.7-37.3)). The overall 24-/48-month secukinumab retention rates were 61%/51% in axSpA, and 63%/49% in PsA patients, respectively. The 24-/48-month secukinumab retention rates in axSpA were significantly higher in bio-naïve patients than in patients treated with 1 or ≥2 prior b/tsDMARDs (Figure 1). In PsA patients, both 24-/48-month secukinumab retention rates were similar between bio-naïve patients and patients who previously received 1 prior b/tsDMARD, and numerically lower in patients having received ≥2 b/tsDMARDs (Figure 2). In axSpA patients, ASDAS-CRP low disease activity (LDA) and ASDAS-CRP clinically important improvement (CII) crude rates were numerically higher in the bio-naïve group at 24 and 48 months. After confounder adjustment, bio-naïve patients had higher rates of ASDAS-CRP LDA than patients who had previously received one or more b/tsDMARDs (Table 1). Similarly, the crude proportions of PsA patients achieving DAPSA28 LDA or moderate response were numerically (but not statistically significantly) higher in the bio-naïve group (Table 1).
Conclusion: This large real-life study showed that secukinumab retention rates after four years wereapproximately 50% in patients with axSpA and PsA. Bio-naïve patients had higher retention, remission and response rates than patients with prior b/tsDMARD exposure, particularly in axSpA.
References 1 https://eurospa.eu/.
To cite this abstract in AMA style:Pons M, Georgiadis S, Faizy Ahmadzay Z, Østergaard M, Glintborg B, Heberg J, Nysom Christiansen S, Horskjær Rasmussen S, Castrejon I, Alonso F, Laas K, Vorobjov S, Khmelinskii N, Zavada J, Ciurea A, Nissen M, Michelsen B, Mielnik P, Loft A, Rotar Z, Perdan Pirkmajer K, Macfarlane G, Jones G, Nordstrom D, Hokkanen A, van der Horst-Bruinsma I, Karlsson Wallman J, Gudbjornsson B, Palsson o, Hetland M, Ørnbjerg L. Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/four-year-secukinumab-treatment-outcomes-in-axial-spondyloarthritis-and-psoriatic-arthritis-patients-treated-in-routine-care-results-from-the-eurospa-collaboration/. Accessed .
« Back to ACR Convergence 2023
ACR Meeting Abstracts - https://acrabstracts.org/abstract/four-year-secukinumab-treatment-outcomes-in-axial-spondyloarthritis-and-psoriatic-arthritis-patients-treated-in-routine-care-results-from-the-eurospa-collaboration/